The earnings period in the global pharma sector has started mainly with positive outlooks and raised targets.
The UK Swedish pharma company AstraZeneca (AZN) stock increased over 11% during the week after positive earnings outlook and sales growth. AstraZeneca stock increased to 11.988 pounds on Friday in London.
The US pharma company Merck (MRK) said they reported strong growth in oncology and vaccines during the first quarter this year. Keytruda sales increased 20% during the period. Company stock increased 4,31% during the week to 131,20 dollars.
The Swiss pharma company Novartis (NOVN) said its top brands like Antresto sales increased 36% to 1,8 billion Swiss francs and Cosentyx’s sales 25% to 1,3 billion Swiss francs.
Novartis said its sales in China increased 31% during the first quarter. Novartis stock increased 4,64% during the week to 89,50 francs.
The French pharma company Sanofi (SAN)said its net sales were 10,4 billion euros. Company stock closed up 4,99% on weekly basis to 91,25 euros on Friday.
The Swiss Sando (SDZ), which was spinn-offed from Novartis last year, gained 5,23% during the week with the biosimilar EU- approval news.
The US pharma company Abbive (ABBV), which increased also its EPS outlook for the full year and completed the Immunogen acquisition, was down 4,08% for the week to 159,62 dollars.
The Swiss pharma company Roche (ROG) was nearly unchanged for the week in Zurich. The company stock closed at 221 Swiss francs, down 0,49% for the week. The company reported Q1 sales of 14,4 billion francs compared to 15,3 billion francs year ago.
ComteamPUB+ 